Davita Inc vs Kinross Gold Corporation — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Kinross Gold Corporation trades at $23.8 (market cap $27.62B). The key difference: Kinross Gold Corporation is far larger — about 2.4× Davita Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Kinross Gold Corporation for 53 Days on average.
| DVA | KGC | |
|---|---|---|
Market Cap | $11.29B | $27.62B |
Volume | 582,204 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $38.06 |
52-Week Low | $103.87 | $22.47 |
Typical Hold Time | 113 Days | 53 Days |
Enterprise Value | $24.01B | $25.70B |
Dividend Yield | — | 0.69% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Kinross Gold Corporation (KGC) trades at $23.18, down 2.65% on the day, amid bearish technical signals despite strong fundamental performance. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $0.71 exceeding expectations, while revenue grew to $7.05 billion in 2025. Analyst consensus remains bullish with a $38.80 price target, though recent news highlights production guidance cuts and legal investigations creating near-term headwinds.
KGC presents a compelling value opportunity with attractive valuation multiples (P/E 8.81, EV/EBITDA 4.58) and strong profitability margins (net income margin 37.52%). However, investors face risks from operational setbacks at key mines, rising production costs, and ongoing legal scrutiny. The stock's current discount to analyst targets suggests potential upside if operational execution improves and gold prices remain supportive.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →